Clinical Trial Update: Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reports on immune responses and safety of recombinant human CD40 ligand in patients with X-linked hyper-IgM syndrome, with the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hyper-igm Syndrome

Drugs mentioned

• Recombinant human CD40 ligand (CD40 ligand)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Immunoproliferative Disorder | Phase 2 | Status: COMPLETED